What Praxis Precision Medicines, Inc. told the SEC could break it.

Praxis runs a 'virtual' model with no in-house manufacturing, relying on CDMOs and on third-party suppliers for key raw materials — some of which are sole-source with no redundant/second-source arrangements.

“We depend on third-party suppliers for key raw materials used in our manufacturing processes, some of which are our sole source of supply, and the loss of these third-party suppliers or their inability to supply us with adequate raw materials could harm our business.”

As a pre-revenue developer, Praxis's future depends on lengthy, unpredictable FDA (and foreign) approval of its candidates (e.g., its ulixacaltamide ET NDA); failure or delay would prevent commercialization.

“The development and commercialization of drug products is subject to extensive regulation, and the regulatory approval processes of the U.S. Food and Drug Administration, or the FDA, and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable.”